What Made H.C. Wainwright Upgrade PDS Biotechnology’s Stock?


H.C. Wainwright analyst Joseph Pantginis upgraded PDS Biotechnology (PDSB) to Buy today and set a price target of $6.00. The company’s shares closed last Monday at $2.04.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 23.6% and a 49.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on PDS Biotechnology is a Moderate Buy with an average price target of $6.30.

See today’s analyst top recommended stocks >>

Based on PDS Biotechnology’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.93 million. In comparison, last year the company had a GAAP net loss of $3.89 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts